Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial.
Kuboki Y, Terazawa T, Masuishi T, Nakamura M, Watanabe J, Ojima H, Makiyama A, Kotaka M, Hara H, Kagawa Y, Sugimoto N, Kawakami H, Takashima A, Kajiwara T, Oki E, Sunakawa Y, Ishihara S, Taniguchi H, Nakajima TE, Morita S, Shirao K, Takenaka N, Ozawa D, Yoshino T. Kuboki Y, et al. Among authors: nakajima te. Br J Cancer. 2023 May;128(10):1897-1905. doi: 10.1038/s41416-023-02212-2. Epub 2023 Mar 4. Br J Cancer. 2023. PMID: 36871043 Free PMC article. Clinical Trial.
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
Nakajima TE, Yasunaga M, Kano Y, Koizumi F, Kato K, Hamaguchi T, Yamada Y, Shirao K, Shimada Y, Matsumura Y. Nakajima TE, et al. Int J Cancer. 2008 May 1;122(9):2148-53. doi: 10.1002/ijc.23381. Int J Cancer. 2008. PMID: 18196580 Free article.
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Matsubara J, Nishina T, Yamada Y, Moriwaki T, Shimoda T, Kajiwara T, Nakajima TE, Kato K, Hamaguchi T, Shimada Y, Okayama Y, Oka T, Shirao K. Matsubara J, et al. Among authors: nakajima te. Br J Cancer. 2008 Feb 26;98(4):832-9. doi: 10.1038/sj.bjc.6604211. Epub 2008 Jan 29. Br J Cancer. 2008. PMID: 18231104 Free PMC article.
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
Matsubara J, Shimada Y, Takashima A, Takahari D, Hirashima Y, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shirao K. Matsubara J, et al. Among authors: nakajima te. Jpn J Clin Oncol. 2008 Aug;38(8):540-6. doi: 10.1093/jjco/hyn062. Epub 2008 Jul 15. Jpn J Clin Oncol. 2008. PMID: 18628316 Clinical Trial.
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
Takashima A, Shirao K, Hirashima Y, Takahari D, Okita NT, Nakajima TE, Kato K, Hamaguchi T, Yamada Y, Shimada Y. Takashima A, et al. Among authors: nakajima te. J Cancer Res Clin Oncol. 2010 Feb;136(2):243-8. doi: 10.1007/s00432-009-0655-8. J Cancer Res Clin Oncol. 2010. PMID: 19727819
113 results